Steve...It looks good...Seems to be positive..Phase II afibercept (Vegf trap)
for meastatic colorectal cancer. A PMH phase II consortium trial..Abstract No:
4027
Citation: J Clin Oncol 26: 2008 (May 20 suppl; abstr 4027)
Author(s): P. Tang, S. J. Cohen, G. A. Bjarnason, C. Kollmannsberger, K. Virik,
M. J. MacKenzie, J. Brown, L. Wang, A. P. Chen, M. J. Moore
Abstract: Background: Vascular endothelial growth factor (VEGF) is an important
target in MCRC. Aflibercept (VEGF Trap) is a recombinant fusion protein of the
human VEGFR1 and R2 extracellular domains and the Fc portion of human IgG1.
Methods: This is an open-label, multi-centre, 2-stage phase II trial in pts with
MCRC. Eligibility criteria: >1 prior systemic therapy for MCRC, ECOG < 2.
Exclusion criteria: prior treatment with a VEGF or VEGFR inhibitor other than
bevacizumab (BEV). IV VEGF Trap (4 mg/kg) was administered every 2 weeks (1
cycle). The primary endpoint was RR and 4-month PFS. Pts were enrolled in two
cohorts: BEV naïve and prior BEV. Planned sample size in each cohort was 40
pts. Results: In total, 51 pts were enrolled (BEV naive = 24 pts; prior BEV =
27; median age=59, range 39-80; M:F = 30:21; ECOG 0:1:2 = 21:27:3; median #
prior regimens for MCRC = 2, range 1-6). After 287 cycles of therapy, most
common treatment adverse events (TAEs) of any grade were (#pts): fatigue (40),
hypertension (28), proteinuria (25), headache (22), voice alteration (16),
anorexia (12), and joint pain (9). Grade 3 TAEs in > 1 pt were (#pts):
hypertension (4), proteinuria (4), fatigue (3), headache (3). One pt died on
treatment due to PD. In the BEV naïve cohort (n=24), 4 pts were inevaluable: 7
pts maintained 4-mo PFS, disease control rate (PR SD > 16 wks) = 29% [95%
CI 13-51%], and median PFS was 2.0 mo [95% CI 1.7- not reached(NR)]. In the
prior BEV cohort (n=27), 1 pt was inevaluable. There was 1 confirmed PR and 7
pts maintained 4-mo PFS, disease control rate 30% [95% CI 14-50%], and median
PFS was 3.4 mo [95% CI 1.9-NR]. Conclusions: Aflibercept (VEGF Trap) is well
tolerated in pretreated pts with MCRC. Single agent activity has been observed
in the prior BEV cohort, and accrual is ongoing in this stratum. Based on the
study results, studies of aflibercept as single agent or in combination should
be explored

Hey Steve,
Been to this rodeo many times in mid May...Lots of spec on June Conferences...
My guess this year is that inst. money is going to follow what is working thru
the summer, and we all know what that is, ad nausium......I live in bio-tech
land...quiet here as far as mergers buyouts etc..I'm guessing after election we
will see some movement...
Good Luck and dont forget to take the dog out !!!! (We can even get on your s#@t
online)heheheh

Nymph...lol..you know i dont trade bio tech...hardly ever!
you are our Bio and druggy here @ Pickr.........lol
thankx for that BTW.......

Steve, Abstracts are coming out in One Hour 16 minutes...I will let you know
asap if their colonrectal drug results are in them. Some of the studies we will
have to wait until the actual conference....If not in the stack I will give you
my best guesses...but at this point I rather be right then guess. Nymph

I was recently reading a book called Life After Life by Dr. Moody. It was a
book about people who had been pronounced "dead" and "came back to life." His
thesis was that we know so much about living but we know so little about dying.
He did not strongly suggest this, but mildly suggested, that there is money to
be made in thinking that people never ever come back from the dead and that
dying is the absolute worst thing possible as we will go to all extents to
"save" a life because we think this is all there is. It's almost heretical to
suggest this in a scientifically minded world although religiously, many people
believe in a life after death, which he hypothesizes maybe could be called life
after life. Was an interesting nugget. You might enjoy reading it. I have
already passed the book on.
Kathy

http://www.stockpickr.com/members/view/answers/46856/

Q: GOLD Reality !

Market saturation of an EVER accumulating element......think about that !
It's never thrown away hence wasted....it's not consumed by us humans......and
it has run it's coarse in industry use...due to them (Corps.) ever seeking
cheaper means of conductivity (golds main use in indust.)....unless
you can tell me GOLD is needed to cure cancer....GOLD is done!

Also consider it's relevance and practicality in today "Modern day Digital
money
world"....A world that is going to only gain by leaps in bounds...very
soon.

There is more people in the world harvesting it from the earth...then any time
in history...wedding jewelry sales worldwide aint going to cut the
mustard........that statement to include CHINA RUSSIA INDIA......gold has lost
it's "mystic" or allure in today's modern day world.....this aint
1849....take
your nugget to the saloon for a warm beer and to lay with a whore and take a
bath.....lol

steve goff

http://www.stockpickr.com/members/view/answers/42696/

Asked by π - 2 month ago - 1 answers - 17 views

Q: Random thought!

If GOLD falls toooo far soon..look for them to break a story, that it (GOLD) is
needed to cure Cancer!
That statement in many ways is plausible.

Gold salts combined with Chloroquine, an anti-malarial, show potential at
treating resistant strains of malaria.

It has been suggested in Japan that gold salts used for the treatment of
Rheumatoid Arthritis particularly gold thioglucose, may also be used for the
treatment of bronchial asthma.

Side effects
Side effects may develop after a significant accumulation of gold in the body.
Gold compounds require up to two months to reach a steady state, and have a
fairly long half life. In 10 days, only 70% is excreted, exacerbating toxicity
problems.[4] The potential benefits for patients with inflammatory bowel
disease, skin rash or a history of bone marrow depression should be weighed
against the potential risks of gold toxicity on previously compromised organ
systems or with decreased reserve. Potential problems with detection and
correct
attribution of toxic effects must also be considered.

Orally administered gold has fewer side effects than intramuscular injections.
Common side effects of oral gold include decreased appetite, nausea, hair
thinning and diarrhea, as well as problems affecting skin, blood, kidneys, or
lungs. Common side effects of injected gold include an itchy skin rash or mouth
sores, with rare instances of kidney problems or suppression of blood cell
production.


Administration
Gold drugs can be administered orally or by intramuscular injection, in which
case it is administered weekly for approximately three to five months before
less-frequent doses begin. Auranofin, in capsule form for oral administration,
is marketed under the brand name Ridaura. Sodium aurothiomalate (Gold sodium
thiomalate as brands Myocrisin UK, Aurolateor or Myochrysine U.S.) and
aurothioglucose (Solganal in U.S.) are administered by injection. Regular urine
tests to check for protein (indicating kidney damage) and blood tests are
needed.


At present, gold salts are infrequently used to treat children with Juvenile
idiopathic arthritis (previously termed Juvenile Rheumatoid Arthritis), as
methotrexate is the convention. Gold salts are sometimes used for children with
progressive polyarthritis who are unresponsive to non-steroidal
anti-inflammatory drugs, methotrexate, and other medications. This treatment is
expensive requiring frequent visits to the doctor and numerous lab tests
-------------------

Auranofin is a organogold compound classified by the World Health Organization
as an antirheumatic agent. Pharmacotheraputic class: Auranofin is an organogold
compound classified by the World Health Organization as an antirheumatic agent

we present gold-based nanoparticles for breast cancer diagnosis and treatment.
The proposed design can become a new method for the treatment of breast cancer
tumors. Our design can eventually lead to clinical trials which will benefit
breast cancer patients worldwide

http://ieeexplore.ieee.org/Xplore/login.jsp?url=/iel5/4252534/4252535/04253280.p

df?temp=x


http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6333901
Asked by π - 15 days ago - 10 answers - 69 views